PL3555099T3 - Sposób wytwarzania inhibitorów btk - Google Patents

Sposób wytwarzania inhibitorów btk

Info

Publication number
PL3555099T3
PL3555099T3 PL17832491T PL17832491T PL3555099T3 PL 3555099 T3 PL3555099 T3 PL 3555099T3 PL 17832491 T PL17832491 T PL 17832491T PL 17832491 T PL17832491 T PL 17832491T PL 3555099 T3 PL3555099 T3 PL 3555099T3
Authority
PL
Poland
Prior art keywords
btk inhibitors
preparing
preparing btk
inhibitors
btk
Prior art date
Application number
PL17832491T
Other languages
English (en)
Inventor
Danial BEAUDRY
Theresa CRAVILLION
Francis Gosselin
Ngiap-Kie LIM
Sushant Malhotra
Qingping Tian
Haiming Zhang
Alexander GMEHLING
Alec Fettes
Stephan Bachmann
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL3555099T3 publication Critical patent/PL3555099T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2409Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2409Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
    • B01J31/2414Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom comprising aliphatic or saturated rings
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/40Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82Metals of the platinum group
    • B01J2531/824Palladium
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09Geometrical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PL17832491T 2016-12-15 2017-12-13 Sposób wytwarzania inhibitorów btk PL3555099T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662434569P 2016-12-15 2016-12-15
EP17832491.9A EP3555099B1 (en) 2016-12-15 2017-12-13 Process for preparing btk inhibitors
PCT/EP2017/082723 WO2018109050A1 (en) 2016-12-15 2017-12-13 Process for preparing btk inhibitors

Publications (1)

Publication Number Publication Date
PL3555099T3 true PL3555099T3 (pl) 2021-12-27

Family

ID=61007648

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17832491T PL3555099T3 (pl) 2016-12-15 2017-12-13 Sposób wytwarzania inhibitorów btk

Country Status (18)

Country Link
US (4) US10385058B2 (pl)
EP (2) EP3825317A3 (pl)
JP (2) JP6800334B2 (pl)
KR (2) KR102375771B1 (pl)
CN (2) CN111333656B (pl)
AR (2) AR110357A1 (pl)
AU (4) AU2017376580B2 (pl)
BR (1) BR112019011247A2 (pl)
CA (2) CA3104116A1 (pl)
ES (1) ES2894262T3 (pl)
HR (1) HRP20211553T1 (pl)
IL (2) IL284690B (pl)
MX (2) MX2020012097A (pl)
PL (1) PL3555099T3 (pl)
SG (2) SG10201913918UA (pl)
SI (1) SI3555099T1 (pl)
TW (3) TWI766176B (pl)
WO (1) WO2018109050A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913918UA (en) 2016-12-15 2020-03-30 Hoffmann La Roche Process for preparing btk inhibitors
US11100492B2 (en) 2018-02-19 2021-08-24 Peter Garrett General purpose re-loadable card aggregation implementation
US20210221792A1 (en) * 2020-01-16 2021-07-22 Hanmi Pharm Co., Ltd. Convergent synthesis of poziotinib derivative
PE20221592A1 (es) 2020-02-20 2022-10-10 Hutchison Medipharma Ltd Compuestos heterociclicos de heteroarilo y usos de los mismos
US20230348471A1 (en) * 2020-06-18 2023-11-02 Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Bruton's tyrosine kinase inhibitor and preparation method therefor
CN116568687A (zh) * 2020-09-21 2023-08-08 和记黄埔医药(上海)有限公司 杂芳基杂环化合物及其用途
WO2022206924A1 (zh) * 2021-04-02 2022-10-06 南京明德新药研发有限公司 含氮三并环双功能化合物及其制备方法和应用
KR20240004918A (ko) 2021-05-05 2024-01-11 에프. 호프만-라 로슈 아게 Btk 억제제 제조 공정
CN113603685A (zh) * 2021-07-23 2021-11-05 都创(上海)医药开发有限公司 Fenebrutinib化合物的晶型及其制备方法和用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3431541A1 (de) * 1984-08-28 1986-03-06 Hoechst Ag, 6230 Frankfurt Cis,endo-2-azabicycloalkan-3-carbonsaeure-derivate, verfahren zu deren herstellung, deren verwendung sowie zwischenprodukte bei deren herstellung
EP2295433A3 (en) * 2003-03-06 2011-07-06 Eisai R&D Management Co., Ltd. JNK inhibitors
AU2006229995A1 (en) * 2005-03-25 2006-10-05 Glaxo Group Limited Process for preparing pyrido(2,3-d)pyrimidin-7-one and 3,4-dihydropyrimido(4,5-d)pyrimidin-2(1H)-one derivatives
AU2008300827B2 (en) 2007-09-19 2013-04-04 4Sc Ag Novel tetrahydrofusedpyridines as histone deacetylase inhibitors
JP5469604B2 (ja) * 2007-09-19 2014-04-16 4エスツェー アクチェンゲゼルシャフト 新規テトラヒドロ融合ピリジン
CN101781312B (zh) * 2009-12-30 2012-09-26 中国科学院广州生物医药与健康研究院 一种吲哚衍生物的合成方法
EP2566869B1 (en) * 2010-05-07 2016-03-02 Gilead Connecticut, Inc. Pyridone and aza-pyridone compounds and methods of use
PE20141686A1 (es) * 2011-11-03 2014-11-08 Hoffmann La Roche Compuestos de piperazina alquilados como inhibidores de actividad btk
US9076830B2 (en) * 2011-11-03 2015-07-07 Applied Materials, Inc. Robot systems and apparatus adapted to transport dual substrates in electronic device manufacturing with wrist drive motors mounted to upper arm
KR20140096100A (ko) * 2011-11-03 2014-08-04 에프. 호프만-라 로슈 아게 이환 피페라진 화합물
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
US8703953B2 (en) * 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
TW201427970A (zh) * 2012-10-12 2014-07-16 Univ Health Network 激酶抑制劑及使用其治療癌症的方法
JP6410790B2 (ja) * 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−2調節因子およびその使用方法
TWI513371B (zh) * 2013-07-08 2015-12-11 Lextar Electronics Corp 整合無線暨有線的照明控制系統
CA2929918C (en) * 2013-12-05 2018-01-23 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
TWI659019B (zh) * 2014-02-28 2019-05-11 日商帝人製藥股份有限公司 吡唑醯胺衍生物
DE102015206627A1 (de) 2014-07-09 2016-01-28 Siemens Aktiengesellschaft Selbstsichernder Umrichter
JP6507234B2 (ja) * 2014-10-02 2019-04-24 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ブルトンチロシンキナーゼ(btk)によって介入される障害の処置における使用のためのピラゾールカルボキサミド化合物
MA41169A (fr) * 2014-12-17 2017-10-24 Acraf Composés antibactériens à large spectre d'activité
PL3233103T3 (pl) * 2014-12-18 2021-04-19 Principia Biopharma Inc. Leczenie pęcherzycy
KR102604425B1 (ko) * 2015-04-29 2023-11-22 난징 산홈 팔마세우티칼 컴퍼니 리미티드 키나아제 억제제로 사용되는 융합 고리 또는 트리시클로아릴피리미딘 화합물
CA2997859C (en) * 2016-02-29 2024-06-04 F. Hoffmann-La Roche Ag Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
SG10201913918UA (en) * 2016-12-15 2020-03-30 Hoffmann La Roche Process for preparing btk inhibitors

Also Published As

Publication number Publication date
EP3825317A2 (en) 2021-05-26
AU2020201260A1 (en) 2020-03-12
EP3555099B1 (en) 2021-08-18
ES2894262T3 (es) 2022-02-14
AU2020201261B2 (en) 2020-11-19
AU2017376580A1 (en) 2019-03-21
KR102375771B1 (ko) 2022-03-17
JP2019535784A (ja) 2019-12-12
JP6800334B2 (ja) 2020-12-16
AU2021201052A1 (en) 2021-03-11
AU2017376580B2 (en) 2020-08-13
KR102257159B1 (ko) 2021-05-28
CA3039090C (en) 2023-09-19
CA3104116A1 (en) 2018-06-21
TWI766176B (zh) 2022-06-01
CN110446710A (zh) 2019-11-12
CN110446710B (zh) 2022-08-02
KR20210002122A (ko) 2021-01-06
US20180230155A1 (en) 2018-08-16
HRP20211553T1 (hr) 2021-12-24
TW201938565A (zh) 2019-10-01
CN111333656B (zh) 2023-03-14
IL265067B (en) 2021-07-29
AR126445A2 (es) 2023-10-11
US10882864B2 (en) 2021-01-05
IL284690A (en) 2021-08-31
TW201940489A (zh) 2019-10-16
US20210079004A1 (en) 2021-03-18
JP2021042228A (ja) 2021-03-18
JP7153705B2 (ja) 2022-10-14
KR20190077090A (ko) 2019-07-02
MX2020012097A (es) 2021-10-06
WO2018109050A1 (en) 2018-06-21
US20200062762A1 (en) 2020-02-27
AR110357A1 (es) 2019-03-20
US10385058B2 (en) 2019-08-20
US20230250103A1 (en) 2023-08-10
IL284690B (en) 2022-07-01
AU2020201260B2 (en) 2020-11-05
AU2020201261A1 (en) 2020-03-12
SG10201913918UA (en) 2020-03-30
SI3555099T1 (sl) 2021-11-30
US11661424B2 (en) 2023-05-30
SG10202009148XA (en) 2020-10-29
EP3555099A1 (en) 2019-10-23
TW201827433A (zh) 2018-08-01
MX2019005527A (es) 2019-08-12
BR112019011247A2 (pt) 2019-10-15
CN111333656A (zh) 2020-06-26
TWI673271B (zh) 2019-10-01
CA3039090A1 (en) 2018-06-21
EP3825317A3 (en) 2021-07-28

Similar Documents

Publication Publication Date Title
HK1246275A1 (zh) 製備ask1抑制劑的方法
IL284690A (en) Process for preparing btk inhibitors
ZA201708142B (en) Process for preparing 4-amino-pyridazines
PL3325443T3 (pl) Sposób otrzymywania pridopidyny
GB201403356D0 (en) A process for preparing a nicotine-containing formulation
SG11201704014WA (en) Process for preparing a polyetheramine
IL252912B (en) Processes for preparing oxathiazine-like compounds
IL274439A (en) Process for making Tapinaroff
PT3295941T (pt) Processo para preparar a forma a do grapiprant
PL3233043T3 (pl) Sposób przygotowania hydrożeli
HK1245792A1 (zh) 製備α-甲酰胺吡咯烷衍生物的方法
IL253877A0 (en) Process for preparing 3-chloro-2-vinylphenylsulfonates
IL248565B (en) A process for the preparation of thiazole derivatives
IL255977B (en) A new process for the preparation of enzalutamide
IL249283A0 (en) Process for the preparation of 3-chloro-2-vinylphenol
GB2511624B (en) Process for acidizing
PL3113919T3 (pl) Sposób powlekania fragmentu powierzchni
ZA201807441B (en) Process for preparing oxathiazin-like compounds
IL253830A0 (en) A process for the preparation of piperidine-4-carbothioamide hydrochloride
PL3209661T3 (pl) Sposób wytwarzania polimorfu rywaroksabanu
GB201417972D0 (en) Process for separatibg materials